



PRESS RELEASE

REGULATED INFORMATION

RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 13 MAY 2016

Mechelen, Belgium, 13 May 2016 – Biocartis Group NV ('Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual general shareholders' meeting ('AGM') in Mechelen today.

The shareholders approved all items on the agenda of the AGM, including the appointment of Mrs. Hilde Eylenbosch as new independent director, as well as the re-appointment as director of Messrs. Roald Borré and Rudi Mariën (acting through Gengest BVBA).

----- END -----

For more information, please contact:

Renate Degrave, Corporate Communications & Investor Relations

rdegrave@biocartis.com

+32 15 631 729

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has four oncology tests and one test for infectious diseases on the market. More information: www.biocartis.com. Follow us at [@Biocartis](https://twitter.com/Biocartis).